Celularity Inc. (NASDAQ:CELUW) Short Interest Up 19.2% in March
Celularity Inc. (NASDAQ:CELUW) Short Interest Up 19.2% in March
Celularity Inc. (NASDAQ:CELUW – Get Rating) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 8,700 shares, an increase of 19.2% from the February 28th total of 7,300 shares. Based on an average trading volume of 19,300 shares, the short-interest ratio is currently 0.5 days.
Celularity Inc.（纳斯达克股票代码：CELUW — Get Rating）在3月份的空头利率大幅增加。截至3月15日，空头利率共计8,700股，较2月28日的7,300股增长了19.2％。根据19,300股的平均交易量，空头利率目前为0.5天。
Celularity Price Performance
Celularity 价格表现
Shares of NASDAQ CELUW remained flat at $0.06 during midday trading on Friday. 56,760 shares of the stock were exchanged, compared to its average volume of 21,241. The firm's fifty day moving average is $0.08. Celularity has a fifty-two week low of $0.05 and a fifty-two week high of $1.99.
周五午盘交易中，纳斯达克CELUW的股价持平至0.06美元。该股交易了56,760股，而平均交易量为21,241股。该公司的五十天移动平均线为0.08美元。Celularity创下五十二周低点0.05美元，五十二周高点为1.99美元。
About Celularity
关于 Celularity
(Get Rating)
（获取评分）
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.
Celularity Inc是一家临床阶段的生物技术公司，开发现成的胎盘衍生异体细胞疗法，用于治疗癌症、免疫和传染病。它通过三个部分运作：细胞疗法、退行性疾病和生物银行。该公司的主要治疗项目包括 CYCART-19，一种胎盘衍生的 CAR-T 疗法，目前处于治疗 B 细胞恶性肿瘤的 I 期临床试验中；CYNK-001，胎盘衍生的未修饰自然杀伤细胞 (NK) 细胞，正在进行治疗急性髓系白血病的 I 期临床试验，以及治疗多形性胶质母细胞瘤和 COVID-19 的 I 期临床试验；CYNK-101 转基因 NK 细胞，正在进行治疗 HER2+ 胃癌和胃食管癌的 I 期临床试验；APPL-001，胎盘-衍生的间充质样粘附基质细胞，处于治疗克罗恩病的临床前阶段；以及 PDA-002，一种胎盘衍生的间充质样粘附基质细胞，处于治疗面部肩胛肌营养不良症的临床前阶段。
Read More
阅读更多
- Get a free copy of the StockNews.com research report on Celularity (CELUW)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
- 免费获取 StockNews.com 关于 Celularity (CELUW) 的研究报告
- MarketBeat Week 回顾 — 3 月 27 日 — 3 月 31 日
- 什么是黄金IRA，它是一种可行的投资吗？
- Braze Inc 准备好飞得更高了吗？
- Mullen Automotive 实现了交付；
- Frontline 能否保持这种势头？
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Celularity Daily 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Celularity及相关公司的最新新闻和分析师评级的简明每日摘要。